share_log

Lyell Immunopharma Analyst Ratings

Lyell Immunopharma Analyst Ratings

莱尔Immunopharma分析师评级
Benzinga ·  2023/08/28 04:47
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
08/28/2023 118.34% JP Morgan $15 → $5 Downgrades Overweight → Neutral
05/05/2023 293.01% HC Wainwright & Co. → $9 Reiterates → Buy
03/02/2023 293.01% HC Wainwright & Co. $11 → $9 Maintains Buy
01/24/2023 74.67% Morgan Stanley $7 → $4 Maintains Equal-Weight
11/14/2022 205.68% Morgan Stanley $15 → $7 Downgrades Overweight → Equal-Weight
11/11/2022 Goldman Sachs Downgrades Buy → Neutral
10/17/2022 424.02% HC Wainwright & Co. → $12 Initiates Coverage On → Buy
05/24/2022 424.02% Goldman Sachs $21 → $12 Maintains Buy
03/31/2022 817.03% Goldman Sachs $31 → $21 Maintains Buy
01/06/2022 773.36% Morgan Stanley $25 → $20 Maintains Overweight
07/12/2021 991.7% Morgan Stanley → $25 Initiates Coverage On → Overweight
07/12/2021 991.7% B of A Securities → $25 Initiates Coverage On → Buy
07/12/2021 860.7% JP Morgan → $22 Initiates Coverage On → Overweight
07/12/2021 1210.04% Goldman Sachs → $30 Initiates Coverage On → Buy
日期 上行/下行 分析公司 目标价格变动 评级变动 之前/当前的评级
08/28/2023 118.34% 摩根大通 15 美元 → 5 美元 降级 超重 → 中性
05/05/2023 293.01% HC Wainwright & Co. → 9 美元 重申 → 购买
03/02/2023 293.01% HC Wainwright & Co. 11 美元 → 9 美元 维护
01/24/2023 74.67% 摩根士丹利 7 美元 → 4 美元 维护 重量相等
11/14/2022 205.68% 摩根士丹利 15 美元 → 7 美元 降级 超重 → 重量相等
11/11/2022 高盛 降级 买入 → 中性
2022 年 10 月 17 日 424.02% HC Wainwright & Co. → 12 美元 启动覆盖范围开启 → 购买
2022 年 5 月 24 日 424.02% 高盛 21 美元 → 12 美元 维护
03/31/2022 817.03% 高盛 31 美元 → 21 美元 维护
01/06/2022 773.36% 摩根士丹利 25 美元 → 20 美元 维护 超重
07/12/2021 991.7% 摩根士丹利 → 25 美元 启动覆盖范围开启 → 超重
07/12/2021 991.7% B of A 类证券 → 25 美元 启动覆盖范围开启 → 购买
07/12/2021 860.7% 摩根大通 → 22 美元 启动覆盖范围开启 → 超重
07/12/2021 1210.04% 高盛 → 30 美元 启动覆盖范围开启 → 购买

What is the target price for Lyell Immunopharma (LYEL)?

Lyell Immunopharma(LYEL)的目标价格是多少?

The latest price target for Lyell Immunopharma (NASDAQ: LYEL) was reported by JP Morgan on August 28, 2023. The analyst firm set a price target for $5.00 expecting LYEL to rise to within 12 months (a possible 118.34% upside). 7 analyst firms have reported ratings in the last year.

摩根大通于2023年8月28日公布了Lyell Immunopharma(纳斯达克股票代码:LYEL)的最新目标股价。该分析公司将目标股价定为5.00美元,预计LYEL将在12个月内上涨至118.34%(可能上涨118.34%)。去年有7家分析公司公布了评级。

What is the most recent analyst rating for Lyell Immunopharma (LYEL)?

Lyell Immunopharma(LYEL)的最新分析师评级是多少?

The latest analyst rating for Lyell Immunopharma (NASDAQ: LYEL) was provided by JP Morgan, and Lyell Immunopharma downgraded their neutral rating.

摩根大通提供了Lyell Immunopharma(纳斯达克股票代码:LYEL)的最新分析师评级,Lyell Immunopharma下调了中性评级。

When is the next analyst rating going to be posted or updated for Lyell Immunopharma (LYEL)?

Lyell Immunopharma(LYEL)的下一次分析师评级何时发布或更新?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lyell Immunopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lyell Immunopharma was filed on August 28, 2023 so you should expect the next rating to be made available sometime around August 28, 2024.

分析师在进行了广泛的研究后得出了股票评级,包括阅读公开财务报表、与Lyell Immunopharma的高管和客户交谈以及听取财报电话会议。大多数分析师每三个月进行一次评级,因此每家公司每年应获得4个评级。Lyell Immunopharma的最后一次评级是在2023年8月28日提交的,因此你应该预计下一个评级将在2024年8月28日左右公布。

Is the Analyst Rating Lyell Immunopharma (LYEL) correct?

分析师对 Lyell Immunopharma(LYEL)的评级是否正确?

While ratings are subjective and will change, the latest Lyell Immunopharma (LYEL) rating was a downgraded with a price target of $15.00 to $5.00. The current price Lyell Immunopharma (LYEL) is trading at is $2.29, which is out of the analyst's predicted range.

尽管评级是主观的,并且会发生变化,但最新的Lyell Immunopharma(LYEL)评级被下调,目标股价为15.00美元至5.00美元。Lyell Immunopharma(LYEL)目前的交易价格为2.29美元,超出了分析师的预期区间。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发